Neuroimaging standards for research into small vessel disease—advances since 2013
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.264 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
Cerebral small vessel disease (SVD) is common during ageing and can present as stroke, cognitive decline, neurobehavioural symptoms, or functional impairment. SVD frequently coexists with neurodegenerative disease, and can exacerbate cognitive and other symptoms and affect activities of daily living. Standards for Reporting Vascular Changes on Neuroimaging 1 (STRIVE-1) categorised and standardised the diverse features of SVD that are visible on structural MRI. Since then, new information on these established SVD markers and novel MRI sequences and imaging features have emerged. As the effect of combined SVD imaging features becomes clearer, a key role for quantitative imaging biomarkers to determine sub-visible tissue damage, subtle abnormalities visible at high-field strength MRI, and lesion-symptom patterns, is also apparent. Together with rapidly emerging machine learning methods, these metrics can more comprehensively capture the effect of SVD on the brain than the structural MRI features alone and serve as intermediary outcomes in clinical trials and future routine practice. Using a similar approach to that adopted in STRIVE-1, we updated the guidance on neuroimaging of vascular changes in studies of ageing and neurodegeneration to create STRIVE-2.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- The Lancet Neurology
- Topic
- Cerebrovascular and Carotid Artery Diseases
- Field
- Medicine
- Canadian institutions
- Ontario Brain InstituteUniversity of TorontoSunnybrook Health Science CentreUniversity of British ColumbiaHotchkiss Brain InstituteFoothills Medical CentreUniversity of Calgary
- Funders
- Daiichi Sankyo EuropeMedical Research CouncilCanadian Institutes of Health ResearchBayer KoreaSanofi GenzymeDirectorate for Biological SciencesNational Institutes of HealthDementias Platform UKUK Dementia Research InstituteEuropean Stroke OrganisationEuropean Academy of NeurologyAlberta InnovatesEVER Neuro PharmaAstraZeneca KoreaNovo NordiskEisaiFondation LeducqAgence Nationale de la RechercheBritish Heart FoundationSanofiGovernment of CanadaBayer VitalBristol-Myers SquibbNestlé Health ScienceConsortium canadien en neurodégénérescence associée au vieillissementAmicus TherapeuticsCanadian Cardiovascular SocietyAlzheimer SocietyAlzheimer's SocietyBiotechnology and Biological Sciences Research CouncilWellcome TrustResearch Councils UKYuhanMcMaster UniversityAlexion PharmaceuticalsPfizerBiogenAlnylam PharmaceuticalsHeart and Stroke Foundation of CanadaUK Research and InnovationEli Lilly and CompanyAstraZenecaSiemens HealthineersAmgenWeston Brain InstituteAmerican Heart Association
- Keywords
- NeuroimagingCognitionDiseaseMedicineNeuroscienceCognitive declineStroke (engine)NeurodegenerationMagnetic resonance imagingPsychologyPathologyRadiologyDementia
- Has abstract in OpenAlex
- no